Extracellular vesicules in amyotrophic lateral sclerosis - from biomarkers to therapeutic targets

Period
2019 - 2020

Coordinator of the consortium: Prof. Hélène Blasco, Imaging and Brain laboratory (iBrain), INSERM / University of Tours - FR

Summary of the consortium

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by degeneration of motor neurons that leads to a progressive muscular paralysis. ALS patients usually die from respiratory insufficiency after 3 to 5 years of disease diagnosis. Nowadays, ALS research is focused on (1) the development of new therapeutic interventions that increase survival and slow disease progression; and (2)  the identification of reliable biomarkers for this disease. Interestingly, brain-derived extracellular vesicles (EVs) can be found in plasma and used as a direct read-out of the status of the central nervous system. A recent study found EVs enriched by pathologic proteins in the plasma of ALS patients in comparison to control subjects. New evidence suggest that EVs rich in pathological proteins could act as scavengers, increasing the cellular clearance of these toxic proteins. However, they can also increase the propagation of pathological proteins to other cells, supporting the prion-like spread of ALS. Therefore, EVs secretion is an important feature for cell clearance and should be maintained, but targeting these EVs and inhibit their spread could represent a neuroprotective strategy against ALS progression.
With this Consortium, we try to establish sustainable collaborations, each partner bringing its specific expertise that can be applied to the development of different projects and new therapeutics for ALS treatment. In an active approach to identify new therapeutic targets and to develop innovative treatments, the general strategy of the team is the search for molecular actors of pathogenesis in ALS by a global "omic" approach, to validate it on different cell types and use small molecules as tools for the development of therapeutic or as a starting point for therapy.

Members of the consortium

Image
Hélène Blasco
Prof.
Hélène
Blasco
University of Tours - FR
Image
Cristina Cereda
Dr
Cristina
Cereda
IRCCS Mondino Foundation - IT
Image
Stephanie Duguez
Dr
Stephanie
Duguez
Ulster University - UK
Image
Jari Koistinaho
Dr
Jari
Koistinaho
University of Eastern Finland - FI
Image
Débora Lanznaster
Dr
Débora
Lanznaster
University of Tours - FR
Image
Ludo Van Den Bosch
Dr
Ludo
Van Den Bosch
Katholieke Universiteit Leuven - BE